Do probiotics work—and for which indication?
A probiotic is not a single treatment category. Benefit is strain-, dose-, population-, and disease-specific; a product with different organisms cannot inherit another product’s evidence.
Direct answer
Some probiotics work for some indications. ‘Improves gut health’ is not a complete claim.
The most consistent outpatient signal is prevention of antibiotic-associated diarrhea with selected strains started near the antibiotic course. Evidence for IBS, IBD, general immunity, mood, weight, and broad microbiome ‘repair’ is inconsistent or product-specific.
Identify the strain
Genus and species are not enough; the alphanumeric strain designation matters.
Match the indication
Antibiotic-associated diarrhea, pouchitis, IBS, and general wellness are different evidence bases.
Count viable organisms
CFU should be guaranteed through the end of shelf life, not only at manufacture.
Storage matters
Temperature and moisture can change viability.
Risk is not zero
Bacteremia or fungemia can occur in highly vulnerable patients.
Bottom lineA product containing the same species—but a different strain, dose, or combination—does not automatically share the same clinical evidence.
Label logic
What must match before evidence can be transferred.
MERHI ONE Evidence Rating
The product and the clinical scenario are inseparable.
Pooling all probiotics can create a misleading average for a product that was never studied.
Selected strains can reduce antibiotic-associated diarrhea in some children and adults.1,4,5
Meta-analyses show a lower relative risk, but benefit varies by strain, antibiotic, age, baseline risk, dose, and timing. LGG and Saccharomyces boulardii have some of the clearest data.
Selected formulations may reduce C. difficile infection during antibiotics.2,3
AGA offers a conditional suggestion for specific strains or combinations; this is not a recommendation for every probiotic and does not replace infection-control or appropriate treatment.
A specific high-dose combination can help prevent recurrent pouchitis after antibiotic-induced remission.2,3
Evidence applies to the studied formulation and surgical population, not to general inflammatory bowel disease.
Probiotics broadly treat IBS, Crohn’s disease, ulcerative colitis, obesity, anxiety, or ‘low immunity.’1,2,3
Results are heterogeneous and many guidelines recommend use only in trials or make no recommendation. Surrogate microbiome changes do not prove patient benefit.
Probiotics are harmless in every patient because they are microorganisms found in food.1,3
Rare systemic infections have occurred, especially with severe illness, immunocompromise, prematurity, central lines, or disrupted barriers.
Brazil ↔ United States
The evidence is shared. Product regulation and labels are not identical.
A study result does not change by country, but legal category, permitted ingredients and claims, formulation, dose on the label, warnings, and quality oversight may differ between FDA and ANVISA frameworks.
United States
Verify the U.S. label, formulation, current FDA status, interactions, and independent quality information.
Brazil
Verify ANVISA-authorized constituents, limits, warnings, claims, formulation, and product regularity.
Product check
Seven fields that a credible probiotic decision needs.
Exact strain
Look for genus, species, and strain code.
Exact indication
Write the outcome the product is supposed to change.
Population
Age, setting, immune status, and baseline risk must resemble the evidence.
Viable dose
Check CFU per daily serving through expiration.
Timing and duration
Prevention and treatment windows are not interchangeable.
Storage
Verify refrigeration and moisture instructions.
Stop criteria
No response, fever, worsening diarrhea, blood, dehydration, or systemic illness needs reassessment.
Common shortcuts
A bigger CFU number is not automatically a better product.
Commercial labels often omit the information needed to connect a product to a trial.
‘50 billion is stronger’
Dose without strain and indication is not interpretable.
‘Ten strains beat one’
More strains do not automatically create more benefit.
‘Clinically studied species’
The studied strain may be different.
‘Repairs the microbiome’
There is no universal healthy microbiome endpoint.
‘Use with every antibiotic’
Absolute benefit depends on baseline risk and patient safety.
‘Fermented food equals probiotic supplement’
Many fermented foods do not contain a documented clinical strain or dose.
Frequently asked questions
Product-specific answers.
When should it start with an antibiotic?+
Some prevention data favor starting within the first days, but the exact strain and patient risk still matter.
Should it be separated from the antibiotic?+
Often yes for bacterial products; follow product-specific guidance. Antifungals affect yeast products.
Does refrigeration mean better?+
No. It means the product has storage requirements; efficacy still needs clinical evidence.
Can healthy adults take one daily forever?+
Long-term routine benefit without a defined indication is not established.
Do probiotics colonize permanently?+
Usually not. Many effects, when present, are transient.
How do I check a Brazilian product?+
Verify the exact strain, current ANVISA notification/status, label claim, CFU, and conditions of use.
Scientific and regulatory sources
Strain-specific evidence before microbiome marketing.
Official guidance is deliberately narrow because products are not interchangeable.
- 01Open source ↗
NIH Office of Dietary Supplements · 2025
Probiotics — Fact Sheet for Health Professionals
- 02Open source ↗
American Gastroenterological Association · 2020
Clinical practice guideline on probiotics in gastrointestinal disorders
- 03Open source ↗
AGA Technical Review · 2020
Technical review on the role of probiotics
- 04Open source ↗
BMJ Open · 2021
Probiotics for prevention of adult antibiotic-associated diarrhea: meta-analysis
- 05Open source ↗
Frontiers in Medicine · 2018
Strain-specificity and disease-specificity of probiotic efficacy
- 06Open source ↗
Agência Nacional de Vigilância Sanitária · 2024–2026
Brazilian supplement rules and notification requirements
- 07Open source ↗
Agência Nacional de Vigilância Sanitária · current
Authorized probiotic constituents and conditions of use
Editorial record